NCT02369016 - Phase III Copanlisib in Rituximab-refractory iNHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2015

Primary Completion Date

October 26, 2022

Study Completion Date

October 26, 2022

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG

Copanlisib (BAY 80-6946)

60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle

Trial Locations (21)

100

Taipei

2013

Johannesburg

3722

Seoul

4000

Plovdiv

16132

Genoa

34093

Istanbul

40138

Bologna

58128

Jeollanam-do

123182

Moscow

420029

Kazan'

440071

Penza

644013

Omsk

650066

Kemerovo

17210-120

Jaú

08270-070

São Paulo

Unknown

São Paulo

115 26

Athens

81-519

Gdynia

03080

Seoul

561-712

Jeollabuk-do

05505

Seoul